Company Overview

Intellia Therapeutics, Inc. is a biotechnology company focused on developing gene-editing therapies using CRISPR/Cas9 technology. The company operates within the biotechnology, genetic medicine, and genomic editing industries, with a primary emphasis on creating potentially curative therapies for severe diseases with high unmet medical need. Intellia’s core business centers on in vivo and ex vivo gene editing approaches, with its research and development activities targeting hereditary diseases, immunological disorders, and oncology applications. The company’s principal revenue sources have historically included collaboration agreements, licensing arrangements, and research funding partnerships, while its long-term strategy is centered on commercialization of therapeutic candidates.

Founded in 2014 and headquartered in Cambridge, Massachusetts, Intellia emerged from foundational CRISPR research developed by scientific pioneers including Jennifer Doudna and collaborators associated with Caribou Biosciences. The company became publicly traded on Nasdaq under the ticker NTLA in 2016. Intellia has positioned itself as one of the early leaders in systemic in vivo CRISPR-based therapeutics, particularly through lipid nanoparticle delivery systems designed to edit genes directly inside the body. Its differentiation has been associated with proprietary genome-editing platforms, intellectual property access, and early clinical development progress in transthyretin amyloidosis and hereditary angioedema programs.

Business Operations

Intellia organizes its operations primarily around therapeutic development programs rather than diversified commercial business segments. Its core platforms include in vivo gene editing, where CRISPR therapies are delivered directly into patients using lipid nanoparticles, and ex vivo gene editing, where cells are modified outside the body and reinfused into patients. The company’s pipeline includes investigational therapies targeting transthyretin amyloidosis, hereditary angioedema, and engineered cell therapies for oncology and autoimmune conditions. Revenue generation has primarily come from strategic collaborations, milestone payments, and licensing agreements rather than product sales, as the company remains in the clinical-stage biotechnology phase.

The company maintains collaborations with major pharmaceutical and biotechnology organizations, including relationships previously or currently involving Regeneron Pharmaceuticals, Novartis, and other research partners disclosed in public filings. Intellia also controls proprietary delivery technologies and gene-editing platforms designed to support precision editing applications. Operations are concentrated largely in the United States, though clinical trial activities and research collaborations involve international sites and regulatory engagement across multiple regions. Intellia’s asset base is heavily weighted toward intellectual property, clinical programs, scientific infrastructure, and manufacturing development capabilities.

Strategic Position & Investments

Intellia’s strategic direction has focused on advancing first-in-class CRISPR therapeutics through clinical development while expanding its delivery capabilities and therapeutic pipeline. The company has invested substantially in lipid nanoparticle delivery systems, manufacturing infrastructure, and translational research intended to support scalable gene-editing treatments. Its lead investigational programs, including NTLA-2001 and NTLA-2002, have represented some of the earliest systemic CRISPR therapies tested in humans, contributing to the company’s visibility within the genomic medicine sector.

The company has also pursued broader pipeline diversification through internal research and external collaborations in oncology, autoimmune disease, and rare genetic disorders. Investments in next-generation editing technologies and cell engineering approaches are intended to strengthen long-term platform capabilities. Intellia’s portfolio strategy emphasizes both wholly owned programs and partnered assets, allowing the company to balance development risk and capital requirements. Public disclosures indicate ongoing investment in manufacturing scale-up and clinical operations to support later-stage development activities.

Geographic Footprint

Intellia Therapeutics is headquartered in Cambridge, Massachusetts, within the broader biotechnology hub of the northeastern United States. Its primary research, development, and corporate operations are concentrated in the U.S., where the company conducts much of its scientific, clinical, and administrative activity. The company participates in clinical development programs involving multiple medical centers and research institutions across North America and selected international markets.

Although Intellia does not operate as a large multinational commercial pharmaceutical company, its partnerships and clinical activities provide it with an international operational presence. Regulatory interactions and clinical trial engagement extend into regions including Europe and other global biotechnology markets. Its collaborative relationships with multinational pharmaceutical companies have also expanded its influence beyond the United States through shared research initiatives and development programs.

Leadership & Governance

Intellia Therapeutics was co-founded by scientists and biotechnology leaders associated with early CRISPR research commercialization efforts. The company’s governance structure reflects a biotechnology-focused leadership model emphasizing scientific innovation, clinical execution, and long-term platform development. Public statements and investor communications have consistently highlighted a strategic vision centered on translating CRISPR gene editing into scalable therapeutic products while maintaining rigorous clinical and regulatory standards.

Key executives include:

• John M. Leonard, M.D. – President and Chief Executive Officer
• Nessan Bermingham, Ph.D. – Founder and Former Executive Leader associated with early company development
• David Lebwohl, M.D. – Chief Medical Officer
• Paula Ragan – Former President and Chief Executive Officer
• Juliette T. Thibault – Executive Vice President and Chief Financial Officer
• Laura Sepp-Lorenzino, Ph.D. – Chief Scientific Officer

The company’s board and executive team include leaders with backgrounds in biotechnology, pharmaceuticals, genomics, and clinical medicine. Governance practices and executive responsibilities are disclosed through public filings including SEC filings and annual corporate governance documentation.